Press Release
Media
Moments We’d Like to Share
-
September 09 2025ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic DisordersLearn More
-
July 28 2025World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related MarketLearn More
-
June 10 2025ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)Learn More
-
April 28 2025ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual MeetingLearn More
-
April 11 2025Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic IngredientsLearn More
-
September 15 2024ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC PatientsLearn More
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
